Introduction
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth most cause of cancer death in the world [@B1]. In China, CRC ranks the top five cancers both in new diagnoses and in the cancer-related cause death [@B2]. The definitive etiology of CRC remains unknown. Evidence suggests that CRC derives from combinations of genetic and environmental factors [@B3]. Previous epidemiological studies have elucidated that inherited susceptibility is a major component of CRC predisposition.

Apoptosis, also called as programmed cell death, is a pivotal mechanism to maintain the normal cellular growth [@B4]. Aberrant functions of apoptosis pathway are associated with the development of CRC [@B5], [@B6]. Caspases are the main regulative and executive enzymes in apoptosis pathway [@B7]. Among them, caspase 8 was one of the most important components of the caspases family proteins [@B5], [@B8]. Caspase 8 plays a critical role in mediating the extrinsic apoptosis pathway [@B9]. The human gene *CASP8* is located on chromosome 2q33‑q34 with 11 exons. Several SNPs of *CASP8* gene have been identified to be associated with cancer risk [@B10]-[@B13]. Among them, *CASP8* rs3834129 polymorphism (-652 6N ins/del), a six six-nucleotide insertion/deletion variant, leads to the decreased expression of *CASP8* mRNA [@B14].

*CASP8* SNPs are reported to predispose to the susceptibility of several cancers, including neuroblastoma [@B12], bladder cancer [@B15], breast cancer [@B13]. Among them, *CASP8* rs3834129, namely -652 6N ins/del polymorphism, is one of the most investigated SNP. Extensively epidemiological studies have assessed the association between *CASP8* rs3834129 (-652 6N ins/del) polymorphism and CRC risk, yet with discrepant results. Therefore, we conducted this meta-analysis to provide a precise evaluation of the association of interest.

Materials and Methods
=====================

Publication search
------------------

We first searched the following key words: \'Caspase 8\' or \'*CASP8*\' or \'rs3834129\' and \'SNP\' or \'polymorphism\' or \'polymorphisms\' or \'single nucleotide polymorphism\' or \'variant\' and \'colorectal cancer\' or \'colorectal tumor\' or \'colorectal carcinoma\' or \'colorectal neoplasm\' or \'CRC\' in database of PubMed and EMBASE. We also searched the Chinese database CNKI and WANFANG to include more eligible studies. Further, additional studies were also manually extracted from the references of the above obtained publications. The latest search was done in March 2018 without any language restriction. The article will be considered as different studies if it contains more than two ethnicities. Among overlapping reports, only the largest one will be retained.

Eligibility criteria
--------------------

The final including studies in this meta-analysis should fulfill all the following requirements: 1) unrelated case-control studies; 2) original epidemiological studies; 3) analyzing the relationship between *CASP8* rs3834129 polymorphism and CRC risk; 4) Sufficient genotype data were presented to obtain odds ratios (ORs) and 95% confidence intervals (CIs); 5) articles written in English or in Chinese.

Data extraction
---------------

We arranged two authors to identify all eligible studies independently. The following items were recorded from each study: first author\'s name, year of publication, Hardy-Weinberg equilibrium (HWE), quality score, country, ethnicity, source of controls, genotyping method, and genotype distributions of cases and controls. All the disagreed information was settle down after fully discussed by the two authors.

Statistical analysis
--------------------

Fisher\'s exact test was applied to check whether the genotype frequency distribution of rs3834129 in controls was deviated from Hardy-Weinberg equilibrium. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from multivariate logistic regression, and then used to estimate the associations between rs3834129 and CRC risk. Subgroup analyses were performed by ethnicity, source of control, and quality score. Between-study heterogeneity was determined by a chi-square-based *Q*-Test. The random-effects model (the DerSimonian and Laird method) would be performed in the presence of heterogeneity, whereas the fixed-effects model (the Mantel-Haenszel method) would be performed. Publication bias was assessed by visual inspection of funnel plots and the Egger\'s linear regression test. The asymmetric plot and P value less than 0.5 was considered as the existence of publication bias. In addition, sensitivity analysis was also applied to assess the robustness of the results. Quality assessment for each study was performed using the quality assessment criteria (Table [1](#T1){ref-type="table"}). The meta-analysis was conducted using STATA version 11.0 (Stata Corporation, College Station, TX, USA). All p values were two-sided.

Results
=======

Study characteristics
---------------------

Using the above mentioned database, we firstly identified 59 potentially relevant published records. After literature screening and abstracts reading, we kept 7 publications in the analysis [@B16]-[@B22]. We also extracted 1 article from the references of the retrieval articles [@B23]. The general work flow of the selection process was graphically shown in Figure [1](#F1){ref-type="fig"}. In all, 13 studies (8 publications) with 13058 cases and 14418 controls were used in the pooled analysis (Table [2](#T2){ref-type="table"}). Among them, 4 studies focused on Asians and 9 on Caucasians. 4 studies were hospital-based design, 9 were population-based design. 6 studies with a quality score \>9, and 7 studies with a quality score ≤9.

Meta-analysis results
---------------------

Overall meta-analysis information was shown in Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. In the pooled analysis, statistically significant protection role of *CASP8* rs3834129 polymorphism in CRC was observed among heterozygous models (ID vs. II: OR=0.94, 95% CI=0.88-0.99). Statistically significant relationship was not observed in homozygous and allele model. When stratified by population, significant association between *CASP8* rs3834129 polymorphism and CRC risk was detected among African (ID vs. II: OR=0.86, 95% CI=0.76-0.98). Such association was not observed for the Caucasians. In terms of source of controls, we failed to detect any significant relationship in hospital-based group and in population-based group. Further subgroup analysis by quality score yielded a significant association for allele model (D vs. I: OR=0.90, 95% CI=0.81-1.00).

Heterogeneity and sensitivity analysis
--------------------------------------

We first used I^2^ statistics and *Q* test to calculate between-study heterogeneity. Significant heterogeneity was detected among all three genetic models (*P*\<0.001) in the pooled analysis. Therefore, we adopted the random-effect model to generate wider CIs. We also conducted sequential leave-one-out sensitivity analysis to assess the stability of the results. The results showed that no substantial changes in pooled results, after removing each study (Figure [3](#F3){ref-type="fig"}).

Publication bias
----------------

The Begg\'s funnel plots of the included studies showed no evidence of obvious asymmetry (Figure [4](#F4){ref-type="fig"}). Moreover, none-existence of publication bias among the studies was also approved by statistical evidence of Egger\'s test (data not shown).

Discussion
==========

In this present meta-analysis, we comprehendsively assessed the relationship between *CASP8* rs3834129 polymorphism with CRC susceptibility. The obtained results suggested *CASP8* rs3834129 polymorphism may influence CRC risk in a low impact effect manner. To date, this meta-analysis represents the most powerful investigation in elucidating the role of *CASP8* rs3834129 polymorphism in CRC risk.

The role of *CASP8* rs3834129 polymorphism in CRC risk has attracted intensive attentions. The first case-control study with 4995 cases and 4972 controls was conducted by Sun et al. in 2007 [@B16]. They identified that -652 6N deletion allele would decrease the susceptibility of lung, colorectal, esophageal, breast, cervical and gastric cancer. Further biochemical assays illustrated that this variant might lead to decreased apoptotic reactivity of T lymphocytes upon cancer cells stimulation. A multi-centric study conducted by Pardini et al. indicated that rs3834129 was not associated with CRC risk in the full data set [@B21]. This study recruited 6,733 CRC cases and 7,576 controls by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (Colorectal cancer GENeTics). Such null associations were also presented in a study conducted by Xiao MS et al. in Chinese population using 305 CRC patients and 342 healthy individuals [@B20].

To further clarify the role of *CASP8* rs3834129 polymorphism on the risk of CRC, we performed this meta-analysis. *CASP8* rs3834129 polymorphism was not associated with CRC risk, in some genetic models. This phenomenon may be due to the relatively small sample or the weak impact of single polymorphism in singe gene. Stratified analysis by ethnicity showed that significant association was observed between *CASP8* rs3834129 polymorphism and CRC risk among Asian, but not Caucasian. Allelic distributions of*CASP8* rs3834129 polymorphisms could vary geographically and ethnically.

When interpreting this meta-analysis, several limitations should be noted. First, we only used unadjusted estimates to assess the strength of association between *CASP8* rs3834129 polymorphism and CRC risk. We failed to conduct adjustment analysis as we could not obtain original data such as life habitat, environmental exposes, and gene-environment interactions, which restrains our further analysis for confounding factors. Second, language bias and selection bias could not be ruled out, as only published studies and papers written in English or Chinese were analyzed. Third, significant between-study heterogeneity was detected, which would impair the validity of conclusion. Fourth, in some subgroup analysis, the sample size was relatively small. Thus, the statistical power is to be impaired to estimate the real association. Last, nearly all the eligible case-control studies included were conducted in Asians and Caucasians. The studies of other ethnicities, such as Africans, were absence. Therefore, more studies from other ethnicities, especially Africans, are necessary to further confirm such conclusion, due to the geographical and genetic differences.

Conclusion
==========

In conclusion, the current meta-analysis provides strong evidence that *CASP8* rs3834129 polymorphism may not be strong enough to impact the risk of CRC, from the perspective of the formed case-control studies. Such relationship further helps to explain the etiology of CRC. Yet, further case-control studies with larger sample sizes, standardized unbiased design are warranted to confirm our findings.
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###### 

Score of quality assessment

  Criteria                                            Score
  --------------------------------------------------- -------
  **Representativeness of cases**                     
  Selected from population cancer registry            2
  Selected from hospital                              1
  No method of selection described                    0
  **Representativeness of controls**                  
  Population-based                                    3
  Blood donors                                        2
  Hospital-based                                      1
  Not described                                       0
  **Ascertainment of cancer cases**                   
  Histopathologic confirmation                        2
  Patient medical record                              1
  Not described                                       0
  **Control selection**                               
  Controls matched with cases by age and sex          2
  Controls matched with cases only by age or by sex   1
  Not matched or not descried                         0
  **Genotyping examination**                          
  Genotyping done blindly and quality control         2
  Only genotyping done blindly or quality control     1
  Unblinded and without quality control               0
  **Total sample size for both cases and controls**   
  Larger than 1000                                    3
  Larger than 500, but less than 1000                 2
  Larger than 200, but less than 500                  1
  Less than 200                                       0

###### 

Characteristics of studies included in the current meta-analysis

  Surname          Year   Country       Ethnicity   Control Source   Genotype method   Case   Control   MAF   HWE                                     
  ---------------- ------ ------------- ----------- ---------------- ----------------- ------ --------- ----- ------ ----- ------ ----- ------ ------ -------
  Sun              2007   China         Asian       PB               PCR-RFLP          605    280       33    918    528   304    58    890    0.24   0.116
  Pittman          2008   England       Caucasian   PB               AS-PCR            995    1897      987   3879   892   1872   897   3661   0.50   0.170
  Liu              2010   China         Asian       PB               PCR-RFLP          233    116       21    370    528   278    32    838    0.20   0.538
  Theodoropoulos   2011   Greece        Caucasian   HB               RFLP-PCR          103    201       98    402    120   254    106   480    0.49   0.194
  Xiao             2013   China         Asian       HB               PCR-PAGE          187    107       11    305    212   115    15    342    0.21   0.905
  Wu               2013   China         Asian       HB               PCR-SSCP          284    152       15    451    358   244    29    631    0.24   0.119
  Pardini          2014   Spain         Caucasian   PB               Taqman            500    996       482   1978   425   802    420   1647   0.50   0.290
  Pardini          2014   Italy         Caucasian   PB               Taqman            195    285       137   617    783   1230   538   2551   0.45   0.178
  Pardini          2014   USA           Caucasian   PB               Taqman            237    514       259   1010   383   794    403   1580   0.51   0.835
  Pardini          2014   England       Caucasian   PB               Taqman            410    825       341   1576   165   393    209   767    0.53   0.436
  Pardini          2014   Czech         Caucasian   PB               Taqman            239    479       249   967    169   326    177   672    0.51   0.443
  Pardini          2014   Netherlands   Caucasian   PB               Taqman            169    282       134   585    106   177    76    359    0.46   0.895
  Diego Marques    2017   Brazil        Caucasian   HB               PCR               49     64        27    140    42    65     33    140    0.47   0.424

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; PB, population based; HB, hospital based; PCR-PAGE, polymerase chain reaction-polyacrylamide gel electrophoresis; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, allele-specific polymerase chain reaction.

###### 

Meta-analysis of the association between *CASP8* rs3834129 (-652 6N Ins/Del) polymorphism and CRC risk

  Variables            No. of   Homozygous                    Heterozygous                      Allele                 
  -------------------- -------- ------------------ ------- -- ---------------------- ------- -- ---------------------- -------
  All                  13       0.92 (0.82-1.04)   0.022      **0.94 (0.88-0.99)**   0.602      0.95 (0.90-1.01)       0.015
  Ethnicity                                                                                                            
  Asian                4        0.78 (0.47-1.32)   0.028      **0.86 (0.76-0.98)**   0.734      0.88 (0.74-1.04)       0.046
  Caucasian            9        0.96 (0.87-1.06)   0.166      0.96 (0.90-1.02)       0.408      0.98 (0.93-1.03)       0.191
  Source of controls                                                                                                   
  PB                   9        0.93 (0.81-1.07)   0.007      0.94 (0.89-1.00)       0.566      0.96 (0.90-1.02)       0.009
  HB                   4        0.88 (0.67-1.16)   0.493      0.89 (0.75-1.04)       0.469      0.02 (0.81-1.05)       0.279
  Quality score                                                                                                        
  \>9                  6        0.82 (0.64-1.06)   0.004      0.91 (0.82-1.02)       0.174      **0.90 (0.81-1.00)**   0.006
  ≤9                   7        1.00 (0.91-1.10)   0.925      0.95 (0.87-1.02)       0.891      1.00 (0.96-1.05)       0.942

Het, heterogeneity; HB, hospital based; PB, population based.
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